AB-NK234-4 CSF1R -3 Antibody

Pan-specific polyclonal antibody for monitoring the expression of human protein-tyrosine kinase CSF1R (Fms)



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Target Protein	
Name Long:	Macrophage colony-stimulating factor 1 receptor
Alias:	CD115; C-fms; Colony stimulating factor 1 receptor; CSF-1-R; CSFMR; FMS; Fms proto-oncogene; Kinase CSFR; Macrophage colony stimulating factor I receptor precursor; M-CSFR; FIM2; FIM2; CCDS4302.1; A2VDG3; Q6LEI2; ENSG00000182578
UniProt ID:	P07333
Sequence Predicted Mass (KDa):	107.984 (972 AA; P07333); 33.248 (306 AA; P07333-2)
Observed SDS-PAGE Mass (KDa):	120-130
Immunogen	
Antibody Immunogen Source:	Human CSF1R (Fms) sequence peptide Cat. No.: PE-01ATR80
Antibody Immunogen Sequence:	CLSSEQNLIQEVTVGE
Location in Target:	Corresponds to amino acid residues L303 to E317;
Peptide Type:	For pan-specific recognition of target expression levels.
Target Phosphosite:	Not phosphorylated
Production Antibody Host Species:	Rabbit
Antibody Type:	Polyclonal
Antibody Ig Isotype Clone Lot:	Immunoglobulin G
Production Method:	The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Production Method: Antibody Amount:	peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH
	peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Amount:	 peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. 25 μg
Antibody Amount: Antibody Concentration:	 peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. 25 μg 1 mg/ml

AB-NK234-4 CSF1R -3 Antibody



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Applications	
Product Use:	Western blotting Antibody microarrays
Antibody Dilution Recommended:	2 µg/ml for immunoblotting
Antibody Species Reactivity:	Human, mouse, rat and many other mammals
Antibody Positive Controls:	Weak reactivity with recombinant human CSF1R on protein dot blots.
Overall Antibody Specificity:	Very high selectivity
Antibody Cross Reactivities:	No immunoreactivity on protein dot blots with recombinant human Flt3 and Kit.

This product is for in vitro research use only and is not intended for use in humans or animals.